Compare GSK plc (GSK) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hershey Co — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Hershey Co trades at $172.33 (market cap $34.54B). The key difference: GSK plc is far larger — about 2.9× Hershey Co's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | HSY | |
|---|---|---|
Market Cap | $101.34B | $34.54B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $236.28 |
52-Week Low | $36.20 | $162.31 |
Enterprise Value | $121.95B | $39.34B |
Dividend Yield | 3.49% | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Hershey (HSY) trades at $171.46, down 2.16% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.35 exceeding expectations. Revenue growth remains steady, and the company benefits from easing cocoa costs and margin recovery. Recent corporate actions include a $1.45 dividend payment scheduled for June 2026.
The outlook for HSY is cautiously optimistic, driven by margin improvement and innovation, though near-term price pressure and competitive risks persist. The consensus price target of $209.25 suggests upside potential, but investors should monitor execution on H2 2026 guidance and input cost trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
